Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Randomized, Placebo Controlled, Double Blind Study to Evaluate the Effects of up to 24 Weeks of Low Dose Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia

NCT03850964 is registered in ClinicalTrials.gov with Cure HHT as lead sponsor.

NCT NCT03850964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03850964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Randomized, Placebo Controlled, Double Blind Study to Evaluate the Effects of up to 24 Weeks of Low Dose Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia
Lead sponsor
Cure HHT
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
May 8, 2023
Completion date
July 31, 2026
Enrollment
70 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, epistaxis, hereditary hemorrhagic telangiectasia, hht, nosebleed